US appeals court turns down Niaspan end-payors' attempt at class certification in antitrust case
MLex Summary: AbbVie and Teva Pharmaceuticals got a US appeals court to rule in their favor against class certification in a case accusing them of conspiring to delay generic Niaspan. The...To view the full article, register now.
Already a subscriber? Click here to view full article